These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 19842941

  • 1. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
    Julià A, Barceló M, Erra A, Palacio C, Marsal S.
    Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
    [Abstract] [Full Text] [Related]

  • 2. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 3. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC.
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab.
    Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A, Chiocchia G.
    Arthritis Rheum; 2010 Aug; 62(8):2262-71. PubMed ID: 20506202
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [Abstract] [Full Text] [Related]

  • 6. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP.
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P, Dörner T, Tony HP.
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [Abstract] [Full Text] [Related]

  • 8. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
    Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M.
    Scand J Immunol; 2004 Jun; 60(1-2):209-18. PubMed ID: 15238091
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.
    Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL.
    Ann Rheum Dis; 2011 Jun; 70(6):1153-9. PubMed ID: 21444302
    [Abstract] [Full Text] [Related]

  • 10. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab.
    Hogan VE, Holweg CT, Choy DF, Kummerfeld SK, Hackney JA, Teng YK, Townsend MJ, van Laar JM.
    Ann Rheum Dis; 2012 Nov; 71(11):1888-94. PubMed ID: 22736099
    [Abstract] [Full Text] [Related]

  • 11. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM.
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L, Lombardi S, Fabris M, Masolini P, Saracco M, Pellerito R, De Vita S.
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [Abstract] [Full Text] [Related]

  • 13. Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis.
    Rioja I, Clayton CL, Graham SJ, Life PF, Dickson MC.
    Arthritis Res Ther; 2005 Sep; 7(1):R101-17. PubMed ID: 15642130
    [Abstract] [Full Text] [Related]

  • 14. A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis.
    Szodoray P, Alex P, Frank MB, Turner M, Turner S, Knowlton N, Cadwell C, Dozmorov I, Tang Y, Wilson PC, Jonsson R, Centola M.
    Rheumatology (Oxford); 2006 Dec; 45(12):1466-76. PubMed ID: 16638801
    [Abstract] [Full Text] [Related]

  • 15. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 16. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [Abstract] [Full Text] [Related]

  • 17. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [Abstract] [Full Text] [Related]

  • 18. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.
    Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
    [Abstract] [Full Text] [Related]

  • 19. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 20. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis.
    van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, van Schaardenburg D, Verweij CL.
    Arthritis Rheum; 2010 Mar; 62(3):694-704. PubMed ID: 20131234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.